What is Celebrex?
Celebrex is the brand name for celecoxib, a non-steroidal antiinflammatory used to relieve the pain, swelling and stiffness of osteoarthritis and adult rheumatoid arthritis; to treat of primary dysmenorrhea; and to reduce intestinal polyps in the inherited disorder adenomatous polyposis.
Reasons taken & Efficacy
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Pain | 20 |
|
|
|
4 | ||
| Other | 14 |
|
|
2 | |||
| Slow my ALS progress | 10 | 0 | |||||
| disease-related symptoms | 3 | 0 | |||||
| maintain weight | 1 | 0 | |||||
| General health | 1 | 0 |
See all 35 patients currently taking Celebrex
Mouse over the table for more information
Side Effects
Dosages
Stop Reasons
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Did not seem to work
|
13 | 48% |
|
|
Doctor's advice
|
5 | 19% |
|
|
Side effects too severe
|
5 | 19% |
|
|
Other
|
4 | 15% |
|
|
Course of treatment ended
|
3 | 11% |
|
|
Personal research
|
2 | 7% |
|
|
Not indicated
|
2 | 7% |
|
Adherence, Burden & Cost See details from patient evaluations ▼
See more information, including instructions, precautions, side effects, and interactions.
Patient Evaluations
See all 5 patient evaluations
-
- gailHD
- Sex: F
- Mouth/throat: moderate
- Arms: severe
- Chest: none
- Legs: severe
- See profile
-
-
- gailHD
- 100 mg daily
- since Aug 19, 2008
-
Efficacy
Major
for Other
-
Side Effects
None
- See full evaluation
-
- old goat
- Sex: M
- Mouth/throat: none
- Arms: mild
- Chest: none
- Legs: moderate
- Type: Upper Motor Neuron
- See profile
-
-
- old goat
- 200 mg daily
- since Sep 16, 2008
-
Efficacy
Moderate
for Other
-
Side Effects
None
- See full evaluation
-
- NicoleH
- Sex: F
- Mouth/throat: mild
- Arms: mild
- Chest: none
- Legs: moderate
- Type: Upper Motor Neuron
- See profile
-
-
- NicoleH
- since Oct 20, 2008
-
Efficacy
Can't tell
for Pain
-
Side Effects
Severe
- See full evaluation
See all 5 patient evaluations
Report created on November 21, 2009.